Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Quantitative hypermethylation of NMDAR2B in human gastric cancer.

Liu JW, Kim MS, Nagpal J, Yamashita K, Poeta L, Chang X, Lee J, Park HL, Jeronimo C, Westra WH, Mori M, Moon C, Trink B, Sidransky D.

Int J Cancer. 2007 Nov 1;121(9):1994-2000.

2.

N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer.

Kim MS, Yamashita K, Baek JH, Park HL, Carvalho AL, Osada M, Hoque MO, Upadhyay S, Mori M, Moon C, Sidransky D.

Cancer Res. 2006 Apr 1;66(7):3409-18.

3.

Aberrant methylation of N-methyl-D-aspartate receptor type 2B (NMDAR2B) in non-small cell carcinoma.

Tamura H, Suzuki M, Moriya Y, Hoshino H, Okamoto T, Yoshida S, Yoshino I.

BMC Cancer. 2011 Jun 5;11:220. doi: 10.1186/1471-2407-11-220.

4.

Down-regulation of thyroid hormone receptor β1 gene expression in gastric cancer involves promoter methylation.

Ling Y, Shi X, Wang Y, Ling X, Li Q.

Biochem Biophys Res Commun. 2014 Feb 7;444(2):147-52. doi: 10.1016/j.bbrc.2014.01.012. Epub 2014 Jan 14.

PMID:
24434154
5.
6.

Epigenetic down-regulation and suppressive role of DCBLD2 in gastric cancer cell proliferation and invasion.

Kim M, Lee KT, Jang HR, Kim JH, Noh SM, Song KS, Cho JS, Jeong HY, Kim SY, Yoo HS, Kim YS.

Mol Cancer Res. 2008 Feb;6(2):222-30. doi: 10.1158/1541-7786.MCR-07-0142.

7.

Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer.

Cheng YY, Jin H, Liu X, Siu JM, Wong YP, Ng EK, Yu J, Leung WK, Sung JJ, Chan FK.

Br J Cancer. 2008 Dec 16;99(12):2083-7. doi: 10.1038/sj.bjc.6604760. Epub 2008 Nov 4.

8.

Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma.

Oshimo Y, Oue N, Mitani Y, Nakayama H, Kitadai Y, Yoshida K, Ito Y, Chayama K, Yasui W.

Pathobiology. 2004;71(3):137-43.

PMID:
15051926
9.

Promoter hypermethylation and silencing of CHFR mitotic stress checkpoint gene in human gastric cancers.

Kang HC, Kim IJ, Park JH, Shin Y, Park HW, Ku JL, Yang HK, Lee KU, Choe KJ, Park JG.

Oncol Rep. 2004 Jul;12(1):129-33.

PMID:
15201973
10.

A promoter methylation pattern in the N-methyl-D-aspartate receptor 2B gene predicts poor prognosis in esophageal squamous cell carcinoma.

Kim MS, Yamashita K, Chae YK, Tokumaru Y, Chang X, Zahurak M, Osada M, Park HL, Chuang A, Califano JA, Sidransky D.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6658-65.

11.

Hypermethylation-modulated down-regulation of CDH1 expression contributes to the progression of esophageal cancer.

Ling ZQ, Li P, Ge MH, Zhao X, Hu FJ, Fang XH, Dong ZM, Mao WM.

Int J Mol Med. 2011 May;27(5):625-35. doi: 10.3892/ijmm.2011.640. Epub 2011 Mar 3.

PMID:
21373750
12.

HOP/OB1/NECC1 promoter DNA is frequently hypermethylated and involved in tumorigenic ability in esophageal squamous cell carcinoma.

Yamashita K, Kim MS, Park HL, Tokumaru Y, Osada M, Inoue H, Mori M, Sidransky D.

Mol Cancer Res. 2008 Jan;6(1):31-41. doi: 10.1158/1541-7786.MCR-07-0213.

13.

Hypermethylation downregulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer.

Chen W, Gao N, Shen Y, Cen JN.

J Gastroenterol Hepatol. 2010 Apr;25(4):823-31. doi: 10.1111/j.1440-1746.2009.06191.x.

PMID:
20492341
14.

The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth.

Kim MS, Chang X, Nagpal JK, Yamashita K, Baek JH, Dasgupta S, Wu G, Osada M, Woo JH, Westra WH, Trink B, Ratovitski EA, Moon C, Sidransky D.

Oncogene. 2008 Mar 27;27(14):2045-54. Epub 2007 Oct 8.

PMID:
17922030
15.

E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas.

Tamura G, Yin J, Wang S, Fleisher AS, Zou T, Abraham JM, Kong D, Smolinski KN, Wilson KT, James SP, Silverberg SG, Nishizuka S, Terashima M, Motoyama T, Meltzer SJ.

J Natl Cancer Inst. 2000 Apr 5;92(7):569-73.

PMID:
10749913
16.

Frequent epigenetic inactivation of RIZ1 by promoter hypermethylation in human gastric carcinoma.

Oshimo Y, Oue N, Mitani Y, Nakayama H, Kitadai Y, Yoshida K, Chayama K, Yasui W.

Int J Cancer. 2004 Jun 10;110(2):212-8.

17.

Co-expression of laminin β3 and γ2 chains and epigenetic inactivation of laminin α3 chain in gastric cancer.

Ii M, Yamamoto H, Taniguchi H, Adachi Y, Nakazawa M, Ohashi H, Tanuma T, Sukawa Y, Suzuki H, Sasaki S, Imai K, Shinomura Y.

Int J Oncol. 2011 Sep;39(3):593-9. doi: 10.3892/ijo.2011.1048. Epub 2011 May 20.

PMID:
21617852
18.

CHD5 is down-regulated through promoter hypermethylation in gastric cancer.

Wang X, Lau KK, So LK, Lam YW.

J Biomed Sci. 2009 Oct 19;16:95. doi: 10.1186/1423-0127-16-95.

19.

Potential utility of HOP homeobox gene promoter methylation as a marker of tumor aggressiveness in gastric cancer.

Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Kokubo K, Kobayashi H, Kim MS, Sidransky D, Watanabe M.

Oncogene. 2010 Jun 3;29(22):3263-75. doi: 10.1038/onc.2010.76. Epub 2010 Mar 15.

PMID:
20228841
20.

Association of NDRG1 gene promoter methylation with reduced NDRG1 expression in gastric cancer cells and tissue specimens.

Chang X, Zhang S, Ma J, Li Z, Zhi Y, Chen J, Lu Y, Dai D.

Cell Biochem Biophys. 2013 May;66(1):93-101. doi: 10.1007/s12013-012-9457-8.

PMID:
23099645

Supplemental Content

Support Center